Antoine Valeri
Overview
Explore the profile of Antoine Valeri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
2472
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Siebert C, Nguyen T, Fourcade A, Zambon A, Saout K, Deruelle C, et al.
Clin Genitourin Cancer
. 2025 Feb;
23(2):102308.
PMID: 40020264
Introduction: Currently, there are no established guidelines for follow-up (FU) after negative prostate biopsies (PBx) despite the presence of a target on MRI. We aimed to evaluate the risk of...
2.
Salgues E, Jeganathan T, Schick U, Nguyen T, Tissot V, Fournier G, et al.
Radiol Med
. 2024 Nov;
129(12):1890-1897.
PMID: 39516434
Background: Prostate cancer ranks as the second most common cancer in men worldwide. Dose escalation to the tumor and/or the prostate improves biochemical recurrence-free survival. However, interobserver variability in lesion...
3.
Jeganathan T, Salgues E, Schick U, Tissot V, Fournier G, Valeri A, et al.
Biomedicines
. 2023 Dec;
11(12).
PMID: 38137530
Introduction: External radiotherapy is a major treatment for localized prostate cancer (PCa). Dose escalation to the whole prostate gland increases biochemical relapse-free survival but also acute and late toxicities. Dose...
4.
Valeri A, Nguyen T
Curr Opin Urol
. 2023 Sep;
33(6):428-436.
PMID: 37727910
Purpose Of Review: Tumor volume and heterogenicity are associated with diagnosis and prognosis of urological cancers, and assessed by conventional imaging. Quantitative imaging, Radiomics, using advanced mathematical analysis may contain...
5.
Nguyen T, Fourcade A, Zambon A, Saout K, Deruelle C, Joulin V, et al.
Urol Oncol
. 2023 Jun;
41(8):354.e11-354.e18.
PMID: 37391283
Introduction: While Prostate Imaging Reporting and Data System (PI-RADS) 4 and 5 lesions usually justify prostate biopsy (PBx), the management of a PI-RADS 3 lesion can be discussed. The aim...
6.
Tremblay G, Nguyen T, Marolleau J, Malhaire J, Fourcade A, Boussion N, et al.
J Contemp Brachytherapy
. 2023 May;
15(2):89-95.
PMID: 37215618
Purpose: As the oncological results of prostate brachytherapy (BT) are excellent for low-risk (LR) or favorable intermediate-risk (FIR) prostate cancer (PCa), evaluating the side effects has become a major issue,...
7.
Lejeune C, Bourredjem A, Binquet C, Cussenot O, Boudrant G, Papillon F, et al.
World J Urol
. 2023 May;
41(6):1541-1549.
PMID: 37173454
Purpose: In diseases where there is no real consensus regarding treatment modalities, promoting shared decision-making can contribute to improving safety and quality of care. This is the case in low-...
8.
Pinot F, Le Pennec R, Abgral R, Blanc-Beguin F, Hennebicq S, Schick U, et al.
Clin Genitourin Cancer
. 2023 Jan;
21(2):248-257.
PMID: 36658064
Introduction: Prostate adenocarcinoma (CaP) is the leading cancer in men. After curative treatment, from 27% to 53% of patients will experience biochemical recurrence (BR). With the development of focal therapies,...
9.
Saout K, Zambon A, Nguyen T, Lucas C, Payrard-Starck C, Segalen T, et al.
Clin Genitourin Cancer
. 2022 Feb;
20(3):e244-e252.
PMID: 35216924
Introduction: A greater selection of candidates for active surveillance (AS) of prostate cancer (PCa) may decrease the rate of delayed treatment. We aimed to study: 1) the impact of MRI...
10.
Bourbonne V, Jaouen V, Nguyen T, Tissot V, Doucet L, Hatt M, et al.
Cancers (Basel)
. 2021 Nov;
13(22).
PMID: 34830828
Significant advances in lymph node involvement (LNI) risk modeling in prostate cancer (PCa) have been achieved with the addition of visual interpretation of magnetic resonance imaging (MRI) data, but it...